NRIXNurix Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $84M
- 54% YoY
- Operating margin
- -340.2%
- 13% YoY
- EBITDA
- −$277M
- 36% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired45% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $30M | $39M | $77M | $55M | $84M | 54% |
| Operating income | −$118M | −$184M | −$155M | −$213M | −$286M | 34% |
| Net income | −$117M | −$180M | −$144M | −$194M | −$264M | 37% |
| Operating cash flow | −$84M | −$160M | −$81M | −$173M | −$249M | 45% |
| Capex | $6M | $12M | $8M | $9M | $14M | 51% |
| Stock-based comp | $16M | $28M | $34M | $34M | $38M | 12% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $699K · 3
- Net
- −$699K
Pay vs performance
No pay-versus-performance disclosure yet.